An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Figure 3

Change in the surface area of nonenhancing lesions in time during BEV treatment in 14 patients evaluable on T2-weighted MRI.